Tengion, Inc. (TNGNQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTengion, Inc. (TNGNQ) trades at $0.00001. Tengion, Inc. was a biotechnology company focused on regenerative medicine, specializing in advanced cellular therapeutic products. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for TNGNQ: TNGNQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Tengion, Inc. (TNGNQ) Healthcare & Pipeline Overview
Tengion, Inc. was a pioneering biotechnology firm dedicated to regenerative medicine, focusing on the development of neo-organs and advanced cellular therapies aimed at improving patient outcomes in chronic kidney disease and bladder cancer.
What Is the Investment Thesis for TNGNQ?
Tengion, Inc. presented a unique proposition in the biotechnology sector with its focus on regenerative medicine and neo-organ development. The company's key value drivers included its innovative therapies, such as Neo-Kidney Augment and Neo-Urinary Conduit, which targeted significant unmet medical needs in chronic kidney disease and bladder cancer. However, the company's financial stability was severely undermined by its eventual bankruptcy filing in 2014, which halted all operations and product development. Investors should note that while the potential for growth in the regenerative medicine sector remains strong, Tengion's past financial performance and current status as a liquidated entity pose substantial risks. The market for regenerative medicine is projected to grow significantly, but Tengion's lack of operational capacity and ongoing financial obligations may hinder any future recovery or value realization.
Based on FMP financials and quantitative analysis
TNGNQ Key Highlights
Market Cap: $0.00B, indicating no current market value due to bankruptcy.
- Beta: 79.90, reflecting extreme volatility and risk associated with the stock.
- Dividend Yield: None, as the company has not issued dividends.
- Employees: 25, indicating a small operational team prior to liquidation.
- Established in 2003, Tengion aimed to innovate in regenerative medicine.
Who Are TNGNQ's Competitors?
TNGNQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| AMGN Amgen Inc. | $403.04 | -1.04% | $218B | 85 5-pillar |
| GILD Gilead Sciences, Inc. | $144.74 | -1.87% | $179B | 64 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TNGNQ's Key Strengths?
Innovative focus on regenerative medicine and neo-organs.
- Established intellectual property rights through licensing agreements.
- Potential to address significant unmet medical needs.
What Are TNGNQ's Weaknesses?
Operations ceased due to Chapter 7 liquidation.
- No current revenue or market capitalization.
- Limited operational capacity with only 25 employees.
What Are the Key Risks for TNGNQ?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles in re-entering the market with new therapies.
- Financial obligations resulting from liquidation proceedings.
- Market competition from established biotechnology firms.
What Threats Does TNGNQ Face?
- Intense competition within the biotechnology sector.
- Regulatory challenges in obtaining approvals for new therapies.
- Market volatility affecting funding and investment opportunities.
What Are TNGNQ's Competitive Advantages?
- Unique focus on neo-organs and regenerative therapies.
- Intellectual property rights providing a competitive edge.
- Innovative approach to addressing significant unmet medical needs.
What Does TNGNQ Do?
Founded in 2003, Tengion, Inc. was a biotechnology company headquartered in Winston-Salem, North Carolina, that specialized in regenerative medicine. The company aimed to revolutionize healthcare through the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, which were often referred to as 'neo-organs.' These innovative products combined living cells with synthetic or natural materials, designed for implantation or injection to integrate and regenerate compromised tissues or organs. Tengion's product pipeline featured two notable experimental therapies: Neo-Kidney Augment, aimed at enhancing kidney function in patients with advanced chronic kidney disease, and Neo-Urinary Conduit, which was in Phase I clinical trials and intended to provide an alternative to intestinal tissue for urinary diversion in bladder cancer patients. The company also held valuable intellectual property related to tissue engineering technology, acquired through a licensing agreement with Children's Medical Center Corporation (CMCC). Despite its innovative approach and potential impact on patient care, Tengion's operations ceased when it voluntarily filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware on December 29, 2014, marking a significant downturn in its trajectory.
What Products and Services Does TNGNQ Offer?
- Develop advanced cellular therapeutic products known as neo-organs.
- Focus on regenerative medicine to improve patient outcomes.
- Conduct clinical trials for innovative therapies targeting chronic diseases.
- Hold intellectual property rights related to tissue engineering technology.
- Aim to commercialize solutions for organ and tissue regeneration.
How Does TNGNQ Make Money?
- Generate revenue through the development and commercialization of therapeutic products.
- Engage in licensing agreements for proprietary technologies.
- Potentially collaborate with healthcare organizations for research funding.
What Industry Does TNGNQ Operate In?
The biotechnology sector, particularly regenerative medicine, is experiencing substantial growth, driven by advancements in cellular therapies and tissue engineering. The global regenerative medicine market is projected to reach approximately $63 billion by 2026, with increasing investment in innovative therapies aimed at chronic diseases. Companies like Tengion, which focus on developing neo-organs, play a critical role in addressing significant healthcare challenges. However, the competitive landscape is intense, with numerous firms vying for market share and funding, making it essential for companies to demonstrate clinical efficacy and regulatory approval to succeed.
Who Are TNGNQ's Key Customers?
- Patients suffering from chronic kidney disease.
- Bladder cancer patients requiring urinary diversion solutions.
- Healthcare providers seeking innovative treatment options.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Tengion, Inc. operates in the Healthcare sector. It is headquartered in Winston-Salem, US. The company is led by CEO David I. Scheer. TNGNQ has traded publicly since 2022.
Key Financial Metrics
Return on equity for Tengion, Inc. stands at 188.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Tengion, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TNGNQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
TNGNQ Latest News
No recent news available for TNGNQ.
TNGNQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TNGNQ.
Price Targets
Wall Street price target analysis for TNGNQ.
TNGNQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TNGNQ; grades run from A+ (80-100) to F (below 30).
Leadership: David I. Scheer
CEO
David I. Scheer has been at the helm of Tengion, Inc., guiding the company through its innovative pursuits in regenerative medicine. With a background in biotechnology and leadership, he has focused on developing advanced cellular therapies aimed at improving patient outcomes. His experience encompasses various roles within the healthcare sector, contributing to his understanding of the complexities involved in bringing new therapies to market.
Track Record: Under David I. Scheer's leadership, Tengion aimed to develop groundbreaking therapies for chronic kidney disease and bladder cancer. His strategic decisions were centered on advancing the company's innovative product pipeline and establishing key partnerships for research and development.
TNGNQ OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like NYSE or NASDAQ. These companies may have less stringent reporting requirements, leading to potential risks for investors, including lower liquidity and transparency.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Increased volatility associated with OTC stocks.
- Lack of comprehensive financial disclosures post-liquidation.
- Verify the status of the company's bankruptcy proceedings.
- Assess any remaining assets or intellectual property.
- Investigate potential restructuring or acquisition opportunities.
- Monitor news for any developments regarding the company's future.
- Review any available financial filings prior to liquidation.
- Previous licensing agreements with reputable institutions.
- Innovative focus on regenerative medicine.
- Established presence in the biotechnology sector prior to liquidation.
Common Questions About TNGNQ (Healthcare)
What are the main risks for TNGNQ?
The main risks for Tengion, Inc. include regulatory hurdles that could impede the re-entry of its therapies into the market, ongoing financial obligations stemming from its Chapter 7 liquidation, and intense competition from established biotechnology firms that may limit its ability to regain market presence.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Company operations ceased following Chapter 7 liquidation in 2014, limiting available data.